UGT1A10 CRISPR Activation Plasmid (h): sc-402837-ACT

UGT1A10 encodes a human UDP-glucuronosyltransferase that catalyzes glucuronidation of diverse endogenous and xenobiotic substrates, increasing their solubility to support phase II detoxification and clearance. This enzyme contributes to metabolic homeostasis by regulating the balance between lipophilic compounds and their excretable glucuronide conjugates, interfacing with intestinal and hepatic drug-metabolizing networks. Variation in UGT1A10 expression or activity can reshape exposure to dietary components, environmental chemicals, and pharmaceuticals, influencing susceptibility to adverse drug responses and chemical stress. As part of the UGT1A gene cluster, UGT1A10 is frequently studied alongside other UGT1A isoforms to resolve isozyme-specific substrate selectivity and pathway compensation.

UGT1A10 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous UGT1A10 expression without altering the underlying DNA sequence.

UGT1A10 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the UGT1A10 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the UGT1A10 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous UGT1A10 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native UGT1A10 locus and enabling the study of UGT1A10-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of UGT1A10 pathway restoration in tumor cells with silenced or reduced UGT1A10 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.